[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"healthy-control\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:healthy-control":76},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,100,123,147,180,205,236,267,290,313,341,372,398],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":77,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":99},"100210159","integrated-cancer-repository-for-cancer-research-100210159",false,"NCT02012699","Integrated Cancer Repository for Cancer Research","iCaRe2","Inclusion Criteria\n\n* Diagnosis\u002Fhistory of cancer\n* Risk for developing cancer or suspicious clinical findings\n* No history of cancer (normal control registry)\n* Able to provide informed consent\n* 19 years of age or older\n* English or Spanish speaking individuals\n\nExclusion Criteria\n\n* Unable to provide informed consent because of cognitive impairment\n* Non-English or non-Spanish speaking individuals",true,"ALL","19 Years","110 Years",{"count":21,"type":22},999999,"ESTIMATED","80 Years","OBSERVATIONAL","The iCaRe2 is a multi-institutional resource created and maintained by the Fred \\& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76],"Pancreatic Cancer","Thyroid Cancer","Lung Cancer","Esophageal Cancer","Thymus Cancer","Colon Cancer","Rectal Cancer","Gastrointestinal Stromal Tumors","Anal Cancer","Bile Duct Cancer","Duodenal Cancer","Gallbladder Cancer","Gastric Cancer","Liver Cancer","Small Intestine Cancer","Peritoneal Surface Malignancies","Familial Adenomatous Polyposis","Lynch Syndrome","Bladder Cancer","Kidney Cancer","Penile Cancer","Prostate Cancer","Testicular Cancer","Ureter Cancer","Urethral Cancer","Hypopharyngeal Cancer","Laryngeal Cancer","Lip Cancer","Oral Cavity Cancer","Nasopharyngeal Cancer","Oropharyngeal Cancer","Paranasal Sinus Cancer","Nasal Cavity Cancer","Salivary Gland Cancer","Skin Cancer","Central Nervous System Tumor","Central Nervous System Cancer","Mesothelioma","Breast Cancer","Leukemia","Melanoma","Sarcoma","Unknown Primary Tumor","Multiple Myeloma","Ovarian Cancer","Endometrial Cancer","Vaginal Cancer","Neuroendocrine Tumors","Plasma Cell Dyscrasia","Healthy Control",[27,28,78,79,80,81,82,83,84,85,65,86,75,76],"Esophageal cancer","Thymus cancer","Pancreatic tumor","Esophageal tumor","Thymus tumor","Thyroid Tumor","Thyroid Nodule","Lung Tumor","Neuroendocrine tumor","RECRUITING","2026-06-25",{"date":90,"type":91},"2026-06-29","ACTUAL",{"date":93,"type":91},"2013-11-01",{"date":95,"type":22},"2099-12",{"name":97,"class":98},"University of Nebraska","OTHER",42,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":16,"sex":17,"minAge":106,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":122},"100638677","an-exploratory-study-on-the-prediction-of-recurrence-risk-of-bipolar-disorder-using-sentiment-analysis-technology-based-on-multi-modal-feature-fusion-100638677","NCT07573839","An Exploratory Study on the Prediction of Recurrence Risk of Bipolar Disorder Using Sentiment Analysis Technology Based on Multi-modal Feature Fusion","Patients group inclusion criteria:\n\n* Patients who have previously met or currently meet the diagnostic criteria for bipolar disorder according to DSM-5, whose condition and treatment are currently stable, and who cooperate with the assessment;\n* Age ≥18 years, \\\u003C65 years;\n* Han Chinese ethnicity;\n* Sufficient visual and auditory abilities to complete the necessary examinations for the study;\n* Understanding the study content and signing the informed consent form. If the patient is unable to sign the informed consent form personally due to low education level or other reasons, it may be signed by a relative or guardian on their behalf.\n\nexclusion criteria:\n\n* The presence of intellectual disability or other conditions that significantly affect the patient's current mental state;\n* the patient has a serious or unstable physical illness, including: neurological disorders (delirium, dementia, stroke, epilepsy, migraine, etc.), congestive heart failure, angina pectoris, myocardial infarction, arrhythmia, hypertension (including untreated or uncontrolled hypertension), malignant tumors, immunodeficiency, and blood glucose levels higher than 12 mmol\u002FL; or other diseases that may interfere with the test assessment (abnormal indicators more than twice the normal value).\n\nHealthy controls group inclusion criteria:\n\n* Age ≥ 18 years, \\\u003C 65 years;\n* Han Chinese ethnicity;\n* Gender matched to the patient group;\n* Sufficient visual and auditory ability to complete the necessary examinations for the study;\n* Understanding of the study content and signing of informed consent;\n* No family history of mental illness. exclusion criteria:\n* Individuals with a mental disorder conforming to DSM-5, or those with suspicious mental symptoms but not meeting the diagnostic criteria;\n* Individuals with severe physical illness that makes it difficult to complete the necessary examinations.","18 Years","64 Years",{"count":109,"type":22},400,"Bipolar disorder (BD) has become a significant public health problem with complex clinical manifestations, difficult treatment, and poor prognosis. However, there is still a lack of effective biological markers for diagnosing and predicting recurrence. Sentiment analysis computing usually refers to using machine equipment to classify, identify, interpret, and imitate human emotions. However, current multi-modal emotion analysis research is mainly based on one or two modalities. Due to the diversity and complexity of patients' emotional expressions, this single- and dual-modal information analysis is far from enough for accurate discrimination of emotional symptoms. Only emotion analysis technology based on multi-modal feature fusion can make more precise and effective judgments. The current project is based on our previous research on cognitive neuroimaging and big data analysis of bipolar disorder. The investigators plan to enroll 200 BD patients who meet DSM-5 diagnostic criteria and 200 healthy controls. The investigators will use sentiment analysis technology with multi-modal feature fusion (text data, audio and visual modalities, eye movements, and electrophysiology) to identify BD recurrence. Biological markers for risk prediction and an algorithm model for joint judgment of multi-source information will be established to analyze the characterization data. The effectiveness of this recurrence prediction model will be further verified and optimized through a large-sample, prospective cohort study design. It is hoped that it can provide a new method for predicting the recurrence risk of BD patients. In the near future, clinical decision-making aids based on this auxiliary method can be developed, and the translational application value of clinical diagnosis and treatment can be explored.",[112,76],"Bipolar Disorder (BD)","2026-05-01",{"date":115,"type":91},"2026-05-07",{"date":117,"type":22},"2026-04",{"date":119,"type":22},"2027-12",{"name":121,"class":98},"Shanghai Mental Health Center",1,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":16,"sex":17,"minAge":106,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":132,"phases":133,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":122},"100491750","phase-1-omar-opioid-use-disorder-100491750","NCT05683184","OMAR Opioid Use Disorder","Characterization of CB1 Receptors Using [11-C]OMAR in Opioid Use Disorder","Inclusion Criteria:\n\n* Able to provide informed consent\n* Male and female 18 years and older\n* DSM-5 diagnosis of opioid use disorder (for OUD group)\n* Physically healthy i.e., no clinically unstable medical conditions\n* Written informed consent and have capacity to consent and comply with study procedures\n\nExclusion Criteria:\n\n* Current neuro-psychiatric illness or severe systemic disease (opioid use disorder is permitted in the OUD group).\n* Presence of ferromagnetic metal in the body or heart pacemaker\n* Have had exposure to ionizing radiation that in combination with the study tracer would result in a cumulative exposure that exceeds recommended exposure limits\n* Are claustrophobic",{"count":131,"type":22},30,"INTERVENTIONAL",[134],"PHASE1","The goal of this research study is to examine the endocannabinoid (eCB) function in vivo in individuals with opioid use disorder (OUD) by measuring cannabinoid receptor 1 (CB1R) availability.",[76,137],"Opioid Use Disorder","2026-04-26",{"date":140,"type":91},"2026-04-28",{"date":142,"type":91},"2023-03-10",{"date":144,"type":22},"2026-12-15",{"name":146,"class":98},"Yale University",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":16,"sex":154,"minAge":106,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":158,"conditions":159,"keywords":166,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":122},"100188602","imaging-cannabinoid-receptors-using-positron-emission-tomography-pet-scanning-100188602","NCT01730781","Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning","Characterization of CB1 Receptors Using [11-C]OMAR","Inclusion Criteria:\n\n* Males ages 18-55\n* For cannabis users:\n* Willing to abstain from cannabis use for four weeks\n* For schizophrenia:\n* Meets DSM-IV-TR criteria for schizophrenia or schizoaffective disorder\n* For prodrome for psychotic illness:\n* Meets SIPS criteria for prodromal syndrome\n* For family history positive:\n* First degree relative with alcoholism\n* For Post-Traumatic Stress Disorder\n* Meets DSM-IV-TR criteria for PTSD\n* For OUD\n* Meets DSM-IV-TR criteria for Opioid Use Disorder\n\nExclusion Criteria:\n\n* Current neuro-psychiatric illness (including cannabis dependence) or severe systemic disease. Cannabis use disorder is permitted in the cannabis dependent group. Schizophrenia and schizoaffective disorder is permitted in the schizophrenia group. Psychotic symptoms are permitted in the prodromal group. Post-Traumatic Stress Disorder is permitted in the PTSD group and Opioid Use Disorder is permitted in the OUD group.\n* Presence of ferromagnetic metal in the body or heart pacemaker\n* Have had exposure to ionizing radiation that in combination with the study tracer would result in a cumulative exposure that exceeds recommended exposure limits\n* Are claustrophobic","MALE","55 Years",{"count":157,"type":22},100,"The aim of the present study is to assess the availability of cannabinoid receptors (CB1R) in the human brain. CB1R are present in everyone's brain, regardless of whether or not someone has used cannabis. The investigators will image brain cannabinoid receptors using Positron Emission Tomography (PET) imaging and the radioligand OMAR, in healthy individuals and several conditions including 1) cannabis use disorders, 2) psychotic disorders, 3) prodrome of psychotic illness and 4) individuals with a family history of alcoholism, 5) Post-Traumatic Stress Disorder 6) Opioid Use Disorder using the PET imaging agent or radiotracer, \\[11C\\]OMAR. This will allow us to characterize the number and distribution of CB1R in these conditions. It is likely that the list of conditions will be expanded after the collection of pilot data and as new data on cannabinoids receptor function and psychiatric disorders becomes available.\n\nThose in the cannabis us disorder arm of the study will have a PET scan on at least three occasions: once while smoking as usual, once after 48-hours of abstinence from cannabis, and a final time after 4 weeks of abstinence. Additional scans may be conducted within the 4 weeks and the last scan may be conducted well beyond 4 weeks. Similarly, while most schizophrenia patients may get scanned just once, a subgroup of patients may get scanned more than once. For example to tease out the effects of medications, unmedicated patients may get scanned while unmedicated and again after treatment with antipsychotic medications. Similarly prodromes may get scanned while in the prodromal stage off medications, on medications and after conversion to schizophrenia.",[160,161,162,163,76,164,165],"Schizophrenia","Cannabis Dependence","Prodromal for Psychotic Illness","Family History of Alcoholism","Opioid-use Disorder","Post Traumatic Stress Disorder",[167,168,160,169,170,171],"Cannabis dependence","Brain Imaging","Control","PTSD","OUD","2026-04-23",{"date":174,"type":91},"2026-04-27",{"date":176,"type":4},"2010-07",{"date":178,"type":22},"2026-12",{"name":146,"class":98},{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":132,"phases":190,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":204},"100572024","predictive-diagnosis-of-ulcero-necrotizing-enterocolitis-in-premature-babies-using-an-artificial-intelligence-approach-based-on-early-analysis-of-the-fecal-microbiota-100572024","NCT06727877","Predictive Diagnosis of Ulcero-Necrotizing EnteroColitis in Premature Babies Using an Artificial Intelligence Approach Based on Early Analysis of the Fecal Microbiota","PECUNIA","Inclusion Criteria:\n\n* Child born prematurely (i.e. before 34 weeks of amenorrhea) in one of participating university hospitals and hospitalized in neonatal intensive care units of the AURA region's university hospitals\n* Child born outside CHU and transferred before 24h of life to the neonatal intensive care unit of one of thehospital participating in the study\n* Affiliated with a Social Security scheme\n\nExclusion Criteria:\n\n* Child whose guardians are protected by law (guardianship, curatorship, safeguard of justice)\n* Children whose parents are under 18 years of age\n* Refusal of parental authority to participate","1 Day",{"count":189,"type":22},1000,[191],"NA","Prematurity affects around 7% of births in France. Necrotizing enterocolitis (NEC) is a dreaded digestive complication. It is responsible for a mortality rate ranging from 15 to 40%, a rate that has remained stable in recent years, and for medium- and long-term digestive and neurodevelopmental morbidity.\n\nIts onset is unpredictable and sudden, usually between 10 and 20 days of life, and requires immediate, aggressive management: hemodynamic support, fasting, systemic antibiotic therapy or even surgery.\n\nPrevention is therefore essential, but systematic measures with proven efficacy (breastfeeding, early enteral feeding, multiple probiotics) are few and far between. What's more, these preventive measures cannot be modulated and adapted individually, since it is not possible to finely predict the risk of developing enterocolitis.\n\nThus, the use of a predictive diagnostic test for NEC would make it possible to identify high-risk premature babies and develop personalized preventive measures.\n\nChanges in the digestive microbiota precede the onset of NEC, but it has not been possible to identify a reproducible and reliable microbial signature. As a result, the limited power of microbiota analysis and interpretation means that it cannot be used in practice to predict ECUN.\n\nOur partner team (MEDiS) has developed a bioinformatics chain (RiboTaxa) to obtain the precise structure of complex microbial communities from direct metagenomic sequencing data. Stool samples from international cohorts (1562 samples, 208 preterm infants) were then mined to train a deep neural network and generate a predictive diagnostic test for NEC. In a local study (10 cases and 10 controls), the predictive diagnostic performance of this test was 90%, with the 1ère stool identified as \"at risk\" preceding NEC by 8 days (extremes 4 - 17 days), and the 2nde by 2 days (extremes 0-7 days). We would now like to test our predictive diagnostic technique on a larger number of premature babies in the AURA region.\n\n1000 children included, 200 children tested (50 NEC - 150 controls)",[194,76],"Necrotizing Enterocolitis (NEC)","2026-04-03",{"date":197,"type":91},"2026-04-06",{"date":199,"type":91},"2025-04-01",{"date":201,"type":22},"2027-06-01",{"name":203,"class":98},"University Hospital, Clermont-Ferrand",5,{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":16,"sex":17,"minAge":213,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":217,"conditions":218,"keywords":220,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":122},"100560723","psychiatric-multi-omics-and-neuroimaging-project-100560723","NCT06580860","Psychiatric Multi-omics and Neuroimaging Project","Psychiatric Multi-omics and Neuroimaging Project Database","PMNP","Inclusion Criteria:\n\n* Age: 13-35 years old(Patients with healthy siblings can be extended to 14-35 years of age)\n* Course of disease: \\\u003C24 months\n* Priority is given to patients who have never taken medicine or duration of drug use \\\u003C 2 weeks\n* No nuclear magnetic contraindications.\n\nExclusion Criteria:\n\n* Family history of psychotic disorders, history of psychoactive substances abuse, alcohol dependence, or nicotine dependence\n* Have a major physical disease or infectious disease\n* History of coma and serious neurological disease 4.MRI contraindications.","13 Years","35 Years",{"count":216,"type":22},1899,"This study focuses on the structure and function of the brain and gene expression in peripheral blood of patients with schizophrenia, to explore the interaction and influence between the three. Patients with mental disorders who have been recruited will take their medication regularly for 1 year and participate in baseline and follow-up assessments.",[219,76],"Mental Disorders",[221,222,223,224,225,226],"schizophrenia","major depressive disorder","autism spectrum disorder","bipolar disorder","magnetic resonance imaging","multi-omics","2026-03-11",{"date":229,"type":91},"2026-03-13",{"date":231,"type":91},"2016-01",{"date":233,"type":22},"2027-01",{"name":235,"class":98},"mingjun Zhong",{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":16,"sex":17,"minAge":106,"maxAge":243,"enrollmentInfo":244,"targetDuration":4,"studyType":132,"phases":246,"briefSummary":247,"conditions":248,"keywords":250,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":122},"100564802","concurrent-tms-fmri-100564802","NCT06633913","Concurrent TMS-fMRI","Neural Effects of Transcranial Magnetic Stimulation Using Concurrent Functional Magnetic Resonance Imaging","Inclusion for patients:\n\n* Diagnosis of major depressive disorder\n* Age greater than or equal to 18 years\n* Age less than or equal to 65 years\n* Able to understand and consent for research participation\n* English-speaking\n\nInclusion for healthy controls:\n\n* Report no lifetime psychiatric diagnosis and treatment\n* scores on Patient Health Questionnaire (PHQ-9) and Generalized Anxiety Disorder Questionnaire (GAD-7) lower than 4\n* Age greater than or equal to 18 years\n* Age less than or equal to 65 years\n* Able to understand and consent for research participation\n* English-speaking\n\nExclusion for all subjects:\n\n* Age less than 18 years\n* Age greater than 65 years\n* With epilepsy or seizure disorder\n* With implanted ferromagnetic equipment in their face or skull near the stimulation target\n\nMRI Exclusion criteria for all subjects:\n\n* Implanted device including pacemaker, coronary stent, defibrillator, or neurostimulation device that is not MRI-compatible\n* Metal in body including bullets, shrapnel, metal slivers\n* Claustrophobia\n* Uncontrolled high blood pressure\n* Blood circulation problems\n* Opiate medication, antihypertensive medication, or any medication that interferes with blood flow (interferes with fMRI recordings)\n* Significant heart disease, such as atrial fibrillation\n* Pregnancy in female participants\n* Prior exposure to deep brain stimulation, rTMS, or tDCS (transcranial direct current stimulation) therapies\n* History of neurological or cardiovascular disorders, brain surgery, radiation treatment, brain hemorrhage or tumor, stroke, or diabetes\n* Significant traumatic brain injury (loss of consciousness, post-injury amnesia, significant radiological\u002Fneurological findings, penetrating brain injury)\n* Refusal to abstain from illicit drug use for duration of the study\n* Refusal to abstain from alcohol within 24 hours of scans\n\nIf you would like to participate in the study, click this link to fill out the Screening Form: https:\u002F\u002Fredcap.icts.uiowa.edu\u002Fredcap\u002Fsurveys\u002F?s=DEYHWF8TMCHHW4Y7. Kindly note that our research team will contact you directly only if you meet the eligibility criteria for the study. Due to the high volume of responses, we are unable to reply to individual inquiries or provide feedback about eligibility decisions.","65 Years",{"count":245,"type":22},97,[191],"The goal of this clinical trial is to examine the neural mechanisms underlying transcranial magnetic stimulation (TMS) using concurrent functional magnetic resonance imaging (fMRI) in both healthy controls (HCs) and patients with high negative affect symptoms, such as depression. Approximately half male and half female participants aged 18-65 will be recruited.\n\nThe main questions it aims to answer are:\n\n1. Is the acute\u002Ftransient effect induced by single-pulse TMS related to the long-term modulatory effect induced by repetitive TMS (rTMS)?\n2. Do any of these effects predict negative affect symptoms, such as depression?\n\nParticipants will:\n\n1. Complete several tests to assess their cognitive abilities and emotional states\n2. Undergo several brain scans, including resting-state fMRI, structural MRI, diffusion tensor imaging (DTI), and task fMRI\n3. Have two different types of TMS sequences, single-pulse and repetitive pulses, administered to specific brain regions while undergoing fMRI",[76,249],"Depression",[249,251,252,253,254,255,256,257],"TMS","fMRI","TMS-fMRI","TBS","Functional Connectivity","Individual Differences","Mood Disorders","2026-03-10",{"date":260,"type":91},"2026-03-12",{"date":262,"type":91},"2024-04-19",{"date":264,"type":22},"2029-01-31",{"name":266,"class":98},"Jing Jiang",{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":16,"sex":17,"minAge":106,"maxAge":274,"enrollmentInfo":275,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":280,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":4},"100622969","perceived-social-support-in-adult-stroke-100622969","NCT07390526","Perceived Social Support in Adult Stroke","The Effect of Perceived Social Support Levels on Life Satisfaction and Social Participation in Adult Stroke Patients","Inclusion Criteria:\n\n* Age between 18 and 75 years\n* Score ≥24 on the Standardized Mini-Mental Test (SMMT) or Mini-Mental State Examination-Education (MMSE-E)\n* Proficiency in Turkish\n* Voluntary participation\n* For the stroke group: clinical diagnosis of stroke at least 3 months prior to enrollment\n* For the stroke group: certified disability rate of at least 20%\n\nExclusion Criteria:\n\n* Unwillingness to participate\n* Presence of major neurological disorders other than stroke\n* Orthopedic disorders affecting the musculoskeletal system\n* Rheumatic disorders affecting the musculoskeletal system\n* For the stroke group: history of multiple strokes\n* For the stroke group: presence of bilateral hemiplegia","75 Years",{"count":276,"type":22},81,"Given the limited evidence in the literature regarding the effect of perceived social support on life satisfaction and social participation in adults with stroke, this study aimed to investigate the effect of perceived social support on these outcomes.",[279,76],"Stroke","NOT_YET_RECRUITING","2026-02-05",{"date":283,"type":91},"2026-02-09",{"date":285,"type":22},"2026-02-15",{"date":287,"type":22},"2026-02-28",{"name":289,"class":98},"Ondokuz Mayıs University",{"id":291,"slug":292,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":16,"sex":17,"minAge":296,"maxAge":274,"enrollmentInfo":297,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":299,"conditions":300,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":122},"100623113","study-on-artificial-intelligence-based-facial-and-speech-related-patterns-in-parkinsons-disease-and-their-digital-biomarkers-100623113","NCT07392411","Study on Artificial Intelligence-Based Facial and Speech-Related Patterns in Parkinson's Disease and Their Digital Biomarkers","Inclusion Criteria:\n\n1. Inclusion Criteria for Parkinson's Disease (PD) Group: (1) Diagnostic Criteria: Meet the diagnostic criteria for Parkinson's disease established by the Movement Disorder Society (MDS) in 2015. (2) Age Range: 18-75 years old. (3) Disease Severity: Early-stage PD: Hoehn-Yahr score ≤ 2.5 points. Mid-to-late-stage PD: Hoehn-Yahr score 2.5-5 points. (4) Consent for Data Collection: Willing to undergo facial expression video and speech audio recording. (5) Informed Consent: Signed informed consent form.\n2. Inclusion Criteria for Parkinson's Plus Syndromes (MSA-P, PSP) Group: (1) Age Range: 18-75 years old. (2) Diagnostic Criteria: MSA patients must meet the diagnostic criteria established by the \\[Chinese Expert Consensus on the Diagnosis of Multiple System Atrophy, 2017\\]. PSP patients must meet the diagnostic criteria established by the \\[Chinese Clinical Diagnostic Criteria for Progressive Supranuclear Palsy, 2016 Edition\\]. (3) Consent for Data Collection: Willing to undergo facial expression video and speech audio recording. (4) Informed Consent: Signed informed consent form.\n\nExclusion Criteria:\n\n1. History of cerebrovascular disease, head trauma, hydrocephalus, brain tumors, or intracranial surgery.\n2. Presence of metal implants, cardiac pacemakers, or other metallic foreign bodies (applies to PD patients).\n3. Severe dyskinesia in PD patients that would compromise cooperation with video\u002Faudio recording.\n4. Mini-Mental State Examination (MMSE) score ≤ 24 points.","15 Years",{"count":298,"type":22},720,"This research employs AI to analyze facial expressions and speech patterns, aiming to develop new digital tools for diagnosing and differentiating Parkinson's disease and similar disorders.",[301,302,303,76],"Parkinson's Disease","Progressive Supranuclear Palsy(PSP)","Multiple System Atrophy","2026-01-30",{"date":306,"type":91},"2026-02-06",{"date":308,"type":91},"2023-07-25",{"date":310,"type":22},"2026-12-31",{"name":312,"class":98},"Beijing Tiantan Hospital",{"id":314,"slug":315,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":16,"sex":17,"minAge":106,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":322,"conditions":323,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":122},"100618173","analysis-of-the-role-of-ige-proteoforms-in-health-and-disease-100618173","NCT07328178","Analysis of the Role of IgE Proteoforms in Health and Disease","IgE-PhD","Inclusion Criteria:\n\n* CSU and type I allergic diseases (including anaphylaxis and desensitization), atopic dermatitis, mastocytosis, XLA and HaT (informed consent, age: any available adult subject, gender: any available subject, clinical phenotype and specific information about the allergy (e.g. severity, medication, medical history, laboratory testing)\n* Healthy controls (informed consent, age matched to the allergic patients, gender matched to the allergic patients, patient-reported symptoms related to allergy to aeroallergens, food, drugs, hymenoptera venom, CSU)\n\nExclusion Criteria:\n\n* Absence of informed consent\n* Age \\\u003C 18 years old",{"count":321,"type":22},200,"The goal of this observational study is to evaluate the role of IgE proteoforms in healthy volunteers and in patients with type I allergy, patients with chronic spontaneous urticaria, patients with a recent history of anaphylaxis, patients with mastocytosis, patients with hereditary alpha tryptasemia, patients with X-linked agammaglobulinemia (XLA), and patients undergoing desensitization for venom or medication allergy.",[324,325,326,327,328,329,330,76,331],"Anaphylaxis","Mastocytosis","X-linked Agammaglobulinaemia","Venom Allergy","Chronic Spontaneous Urticaria (CSU)","Type I Allergy","Medication Allergy","Hereditary Alpha-Tryptasemia","2025-12-26",{"date":334,"type":91},"2026-01-09",{"date":336,"type":91},"2025-01-01",{"date":338,"type":22},"2029-01-01",{"name":340,"class":98},"KU Leuven",{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":347,"eligibilityCriteria":348,"healthyVolunteers":16,"sex":17,"minAge":349,"maxAge":350,"enrollmentInfo":351,"targetDuration":4,"studyType":132,"phases":353,"briefSummary":354,"conditions":355,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":371},"100555436","acoustic-waveform-respiratory-evaluation-100555436","NCT06512064","Acoustic Waveform Respiratory Evaluation","Advancing Telemedicine in Pulmonology: Acoustic-waveform Respiratory Evaluation (AWARE) Via Sensing and Machine Learning on Smartphones","AWARE","Inclusion Criteria:\n\n1. Age 8-70 years\n2. Ability to perform spirometry and oscillometry\n3. Signed informed consent (and assent for children as appropriate)\n4. No respiratory or other major disease (for healthy controls), or physician-diagnosed asthma, COPD, CF, or other airway diseases\n\nExclusion Criteria:\n\n1. Inability or unwillingness to perform AWARE, spirometry, or oscillometry\n2. Acute or chronic illness that, at the judgement of investigators, may affect lung function and alter the results of AWARE or the reference PFTs (spirometry and AOS)","8 Years","70 Years",{"count":352,"type":22},800,[191],"The study will evaluate the feasibility of using smartphone speakers and microphones to evaluate the caliber of the airways, detect airway obstruction, aid in airway disease diagnosis, and identify disease exacerbations.",[356,357,358,359,360,361,76],"Asthma","COPD","Cystic Fibrosis","Ciliary Motility Disorders","Bronchiectasis","Airway Malacia","2025-10-23",{"date":364,"type":91},"2025-10-24",{"date":366,"type":91},"2024-07-23",{"date":368,"type":22},"2029-04",{"name":370,"class":98},"Indiana University",2,{"id":373,"slug":374,"hasResults":11,"nctId":375,"briefTitle":376,"officialTitle":376,"acronym":377,"eligibilityCriteria":378,"healthyVolunteers":16,"sex":17,"minAge":106,"maxAge":243,"enrollmentInfo":379,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":381,"conditions":382,"keywords":384,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":122},"100591036","test-retest-reliability-and-agreement-of-trunk-muscle-activation-in-pain-free-persons-100591036","NCT06975202","Test-retest Reliability and Agreement of Trunk Muscle Activation in Pain-free Persons","MAS-Reliab","Inclusion Criteria:\n\n\\- Pain-free persons between 18 and 65 years old\n\nExclusion Criteria:\n\n* Persons experiencing low back pain in the past year\n* Patients with serious underlying conditions (e.g., multiple sclerosis)\n* Previous spinal surgery\n* Persons with any type of blood clotting disorder\n* Persons with upper-limb complaints that prevent them from exerting (maximum) force with their arms or hands.",{"count":380,"type":22},18,"The aim of the study is to investigate test-retest reliability and agreement of trunk muscle activation during functional tasks and clinical sensorimotor control tests in pain-free persons.",[383,76],"Controls",[385,386,387,388],"reliability","agreement","muscle activation","functional tasks","2025-05-07",{"date":391,"type":91},"2025-05-16",{"date":393,"type":91},"2024-04-02",{"date":395,"type":22},"2025-10-15",{"name":397,"class":98},"University Ghent",{"id":399,"slug":400,"hasResults":11,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":16,"sex":17,"minAge":405,"maxAge":274,"enrollmentInfo":406,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":408,"conditions":409,"keywords":413,"overallStatus":280,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":122},"100357757","dry-eye-syndrome-healthy-control-sjgrens-syndrome-and-other-inflammation-disease-in-taiwan-biobank-100357757","NCT03938207","Dry Eye Syndrome, Healthy Control, Sjögren's Syndrome and Other Inflammation Disease in Taiwan Biobank","The Comprehensive Analysis of Health Records, TCM Constitution, Biomarker, and Whole-genome Sequencing Among Dry Eye Syndrome, Healthy Control, Sjögren's Syndrome and Other Inflammation Disease in Taiwan","Sjögren's syndrome\n\nInclusion Criteria:\n\n1. aged between 20 and 75 years\n2. fulfilled the 2002 American-European Consensus Criteria for SS (AECG) Exclusion Criteria: NA\n\nDry eye syndrome\n\nInclusion Criteria:\n\n1. aged between 20 and 75 years\n2. Schirmer's test less than 10 mm\u002F5 min Exclusion Criteria: NA\n\nInflammation disease\n\nInclusion Criteria:\n\n1. aged between 20 and 75 years\n2. Disease diagnosed with Inflammation Exclusion Criteria: NA","20 Years",{"count":407,"type":22},100000,"The comprehensive analysis of health records, TCM constitution, biomarker, and whole-genome sequencing among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease in Taiwan: an integrated analysis between Taiwan Biobank and Sjögren's syndrome Database",[410,411,76,412],"Dry Eye Syndrome","Sjogren's Syndrome","Inflammation",[414,415,416,417,418,412,419],"Dry eye syndrome","Sjögren's syndrome","Gene modulation","Xerophthalmia","TCM pattern","Healthy control","2022-08-09",{"date":422,"type":91},"2022-08-11",{"date":424,"type":22},"2022-10-01",{"date":426,"type":22},"2027-12-31",{"name":428,"class":429},"Taipei Veterans General Hospital, Taiwan","OTHER_GOV"]